Acrivon Therapeutics (ACRV) Competitors $1.26 -0.02 (-1.56%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.26 0.00 (0.00%) As of 08/1/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. VYGR, DERM, ALEC, LFVN, IMAB, BDTX, BIOA, PBYI, NVCT, and CCCCShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Voyager Therapeutics (VYGR), Journey Medical (DERM), Alector (ALEC), Lifevantage (LFVN), I-Mab (IMAB), Black Diamond Therapeutics (BDTX), BioAge Labs (BIOA), Puma Biotechnology (PBYI), Nuvectis Pharma (NVCT), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Its Competitors Voyager Therapeutics Journey Medical Alector Lifevantage I-Mab Black Diamond Therapeutics BioAge Labs Puma Biotechnology Nuvectis Pharma C4 Therapeutics Voyager Therapeutics (NASDAQ:VYGR) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment. Do insiders & institutionals have more ownership in VYGR or ACRV? 48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 6.4% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to VYGR or ACRV? In the previous week, Voyager Therapeutics had 3 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 3 mentions for Voyager Therapeutics and 0 mentions for Acrivon Therapeutics. Voyager Therapeutics' average media sentiment score of 0.51 beat Acrivon Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Voyager Therapeutics Positive Acrivon Therapeutics Neutral Which has more volatility and risk, VYGR or ACRV? Voyager Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Do analysts rate VYGR or ACRV? Voyager Therapeutics currently has a consensus price target of $13.39, indicating a potential upside of 352.36%. Acrivon Therapeutics has a consensus price target of $17.71, indicating a potential upside of 1,305.90%. Given Acrivon Therapeutics' higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Voyager Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is VYGR or ACRV more profitable? Acrivon Therapeutics has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -126.49%. Voyager Therapeutics' return on equity of -27.36% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-126.49% -27.36% -21.06% Acrivon Therapeutics N/A -44.66%-40.94% Which has preferable earnings & valuation, VYGR or ACRV? Voyager Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$66.96M2.45-$65M-$1.46-2.03Acrivon TherapeuticsN/AN/A-$80.56M-$2.22-0.57 SummaryVoyager Therapeutics beats Acrivon Therapeutics on 8 of the 15 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.50M$2.50B$5.51B$9.35BDividend YieldN/A1.79%4.74%4.14%P/E Ratio-0.578.9028.9723.78Price / SalesN/A693.19444.0897.26Price / CashN/A22.2824.4827.20Price / Book0.224.838.365.61Net Income-$80.56M$31.61M$3.25B$265.26M7 Day Performance-11.89%-4.82%-3.55%-4.34%1 Month Performance-2.70%3.12%5.11%4.11%1 Year Performance-83.31%-2.00%25.34%17.92% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics2.5617 of 5 stars$1.26-1.6%$17.71+1,305.9%-83.3%$39.50MN/A-0.5758VYGRVoyager Therapeutics3.9967 of 5 stars$3.27+0.9%$13.39+309.5%-64.3%$179.29M$80M-2.24100Upcoming EarningsDERMJourney Medical1.9617 of 5 stars$7.68+1.2%$9.50+23.7%+33.7%$176.82M$56.13M-19.6990Positive NewsUpcoming EarningsAnalyst RevisionALECAlector4.0325 of 5 stars$1.76flat$4.17+136.7%-72.6%$175.99M$88.34M-1.40270Upcoming EarningsHigh Trading VolumeLFVNLifevantage3.6874 of 5 stars$13.13-4.2%$30.50+132.3%+50.7%$172.58M$200.16M19.03260IMABI-Mab2.5122 of 5 stars$1.87-11.4%$6.00+220.9%+107.9%$172.30MN/A0.00380News CoverageGap UpHigh Trading VolumeBDTXBlack Diamond Therapeutics2.2868 of 5 stars$2.93-1.3%$12.80+336.9%-55.0%$168.88M$70M48.8390Positive NewsUpcoming EarningsGap DownBIOABioAge LabsN/A$4.53-1.9%N/AN/A$165.63MN/A0.00N/APositive NewsPBYIPuma Biotechnology3.8311 of 5 stars$3.34+1.8%$7.00+109.6%-19.8%$162.79M$230.50M4.34200Upcoming EarningsNVCTNuvectis Pharma2.5255 of 5 stars$7.60-2.3%$17.00+123.7%+10.2%$162.55MN/A-6.738Upcoming EarningsAnalyst RevisionCCCCC4 Therapeutics2.3747 of 5 stars$2.18-3.5%$12.00+450.5%-67.0%$160.48M$35.58M-1.48150Positive News Related Companies and Tools Related Companies Voyager Therapeutics Competitors Journey Medical Competitors Alector Competitors Lifevantage Competitors I-Mab Competitors Black Diamond Therapeutics Competitors BioAge Labs Competitors Puma Biotechnology Competitors Nuvectis Pharma Competitors C4 Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredOut with the old (A.I.) - In with the new (E.I.)One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
